Merrill Lynch Pharma/Biotech & Medical Device Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
Exact Sciences driving PreGen-Plus adoption: Grassroots effort by the firm is under way to get its fecal DNA colorectal cancer screening test included in the American Cancer Society's cancer detection guidelines to help drive adoption. The test recorded about $4.9 mil. in 2004 sales. Exact Sciences also has applied for Medicare inclusion and expects a decision within about nine months, President & CEO Don Hardison said during a Feb. 10 presentation at the Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference in New York. PreGen-Plus was shown to be four times more effective in identifying invasive cancers than Beckman Coulter's market-leading Hemoccult II fecal occult blood test in a recent study in the New England Journal of Medicine (1"The Gray Sheet" Jan. 3, 2005, p. 18)...